Key result
Circulating Elabela shows inconsistent associations with cardiovascular and renal disease severity across existing studies.
Why the study?
Clinical studies associate circulating Elabela (ELA) with cardiovascular and renal conditions, but correlations with disease severity and prognosis are inconsistent. Current evidence relies mainly on small cross-sectional studies lacking standard assay protocols, and heart failure prognosis research remains scarce and contradictory.
This narrative review highlights that circulating Elabela shows inconsistent associations with cardiovascular, renal, and placental disease severity and prognosis, requiring standardized assays and prospective multicenter validation before clinical biomarker adoption.
Answers are grounded in this paper and cite their sources.
Inconsistent associations preclude Elabela use for prognosis; leaves open validation with standardized assays in prospective studies.
Elabela (ELA) is an endogenous ligand that is of critical importance in the modulation of the cardiovascular, renal, and placental physiology.Clinical studies have pointed to an association of circulating levels of ELA with some pathophysiologic conditions, such as coronary artery disease, heart failure, chronic kidney impairment, preeclampsia, and microvascular complications of the diabetes.However, its correlation with the degree of the disease and short-term prognosis is not always consistent; it could dependon: the stage of the disease, timing of the sample collection, renal status, type of specimen, different peptide variants, and the analytical method.Current evidence is mainly from cross-sectional studies with a small sample size and a lack of any standard assay protocol.Research on the prognosis of heart failure is still scarce and gives contradictory findings.In this review, we discuss the biological basis and the clinical correlations of ELA, assesses its limitations by the detection methods and the sample handling, and outline the future directions.In the future, prospective multicenter studies with proven detection methods, prespecified clinical endpoints, and external validation are needed to clarify the clinical benefits of ELA beyond existing biomarkers.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2026) conducted a review in Cardiovascular disease, chronic kidney disease, preeclampsia, and diabetic microvascular complications. Circulating Elabela (ELA) was evaluated. Circulating Elabela shows inconsistent associations with disease severity and prognosis across cardiovascular, renal, and placental conditions due to small cross-sectional designs and unstandardized assays.
Synapse has enriched 10 related papers. Consider them for comparative context: